Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Ugeskr Laeger ; 186(5)2024 01 29.
Article in Danish | MEDLINE | ID: mdl-38327198

ABSTRACT

This case report presents a 69-year-old male patient with a subcutaneous tumour in the left parietal region. Initially, the tumour was identified as a lipoma or benign cyst by the general practitioner. However, a subsequent MRI scan revealed a sarcoma metastasis with a significant intracranial component. Radical excision of the tumour was not possible due to its critical localisation. Therefore, the patient received palliative radiotherapy. This case emphasises the importance of accurate clinical assessment and highlights the clinical features that should lead to suspicion of malignancy.


Subject(s)
Cysts , Lipoma , Sarcoma , Soft Tissue Neoplasms , Male , Humans , Aged , Lipoma/diagnostic imaging , Lipoma/surgery , Magnetic Resonance Imaging
2.
BMJ Case Rep ; 15(12)2022 Dec 14.
Article in English | MEDLINE | ID: mdl-36517080

ABSTRACT

Treatment of induced oligometastatic disease after partial response to systemic antineoplastic therapy in non-small cell lung cancer (NSCLC) remains controversial. The introduction of immune checkpoint inhibitors (ICIs) has revolutionised the treatment of stage IV NSCLC. While ICI combined with chemotherapy (ChT) leads to longer duration of response and higher response rates compared with ChT alone, it can also cause serious adverse events (AEs) resulting in treatment discontinuation. In case of treatment discontinuation due to AEs after partial response to systemic treatment, surgical treatment of residual disease can be considered as it could lead to complete response. We present a case of a patient with stage IV NSCLC who is currently alive without any signs of cancer after partial response to ICI/ChT followed by surgical removal of residual disease.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/pathology , Immunotherapy/adverse effects , Immune Checkpoint Inhibitors/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...